SG Americas Securities LLC Acquires New Position in Mesa Laboratories, Inc. (NASDAQ:MLAB)

SG Americas Securities LLC bought a new stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,327 shares of the medical instruments supplier’s stock, valued at approximately $302,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Mesa Laboratories by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 373,397 shares of the medical instruments supplier’s stock worth $40,973,000 after buying an additional 3,119 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Mesa Laboratories in the first quarter valued at approximately $605,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Mesa Laboratories by 66.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,044 shares of the medical instruments supplier’s stock valued at $553,000 after purchasing an additional 2,010 shares during the period. BNP Paribas Financial Markets raised its position in shares of Mesa Laboratories by 4.5% in the first quarter. BNP Paribas Financial Markets now owns 7,565 shares of the medical instruments supplier’s stock worth $830,000 after acquiring an additional 327 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Mesa Laboratories by 6.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,873 shares of the medical instruments supplier’s stock worth $316,000 after purchasing an additional 175 shares during the period. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on MLAB. StockNews.com downgraded Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Friday. Wells Fargo & Company began coverage on shares of Mesa Laboratories in a research report on Tuesday, August 27th. They issued an “underweight” rating and a $120.00 target price on the stock. Finally, Evercore ISI upped their price target on shares of Mesa Laboratories from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st.

Mesa Laboratories Stock Up 2.1 %

NASDAQ MLAB opened at $135.91 on Friday. Mesa Laboratories, Inc. has a one year low of $82.86 and a one year high of $141.17. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.37 and a current ratio of 1.94. The business has a fifty day moving average price of $127.88 and a 200 day moving average price of $112.96. The company has a market cap of $735.14 million, a P/E ratio of -2.88 and a beta of 0.85.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Monday, August 5th. The medical instruments supplier reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.74 by $0.55. Mesa Laboratories had a negative net margin of 111.89% and a positive return on equity of 18.95%. The firm had revenue of $58.17 million for the quarter, compared to analyst estimates of $55.90 million. Research analysts anticipate that Mesa Laboratories, Inc. will post 7.91 EPS for the current fiscal year.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 29th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Friday, November 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.47%. Mesa Laboratories’s dividend payout ratio is presently -1.36%.

Insider Buying and Selling

In other Mesa Laboratories news, SVP Brian David Archbold sold 1,499 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $125.00, for a total value of $187,375.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.20% of the stock is currently owned by company insiders.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.